GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
Related Articles
Aasma Shaukat, MD, MPH, on A Blood-Based Test for Colorectal Cancer Screening
Aasma Shaukat, MD, MPH, of NYU Langone, presented results from the PREEMPT CRC study, which evaluated the clinical performance of an investigational blood-based screening test…
Optimizing Therapeutic Proteins Through PEGylation: Key Parameters and Impacts
This Webinar examines what is PEGylation and the clinical uses of therapeutic proteins, and their applications in healthcare.
Shedding Light on Cancer’s Lung-Metastatic Propensity
Seeking to understand why the lungs are a favored organ of metastasis, researchers have uncovered a signaling role for the classical metabolite aspartate. In lung-disseminated…
KEYNOTE-756:Neoadjuvant pembro + chemo improves pCR
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Fox Chase Cancer Center Welcomes Weiran Feng, PhD
Weiran Feng, PhD, Assistant Professor in the Nuclear Dynamics and Cancer Research Program and a member of the Cancer Epigenetics Institute (CEI).
Zoldonrasib Shows Promise in KRAS G12D–Mutated PDAC
Zoldonrasib showed preliminary antitumor activity and manageable adverse events in KRAS G12D–mutated PDAC, per phase 1 trial data.
2025 ASTRO Annual Refresher Course – American Society for Radiation Oncology (ASTRO)
Learn more about the 2025 ASTRO Annual Refresher Course.
Epigenomic heterogeneity as a source of tumour evolution
Nature Reviews Cancer – Single-cell epigenomic technologies are refining our understanding of cancer evolution. Here Laisné et al. describe how epigenomic heterogeneity generates dynamic…
Felix Feng: “When a symposium is named after you, you can pretty much just wax poetic up on stage.” Keynote address at The Feng Symposium in May 2024 – The Cancer Letter
On May 18, 2024, Felix Feng, a leader in genitourinary cancer research, gave the keynote address at the inaugural symposium that bears his name. Feng…
Systematic review of nutrition interventions in older patients with cancer: A synthesis of evidence and a future research priority
Older patients with cancer (65 years and older) are a growing population with unique nutrition-and treatment-related issues that accelerate aging. Nutrition interventions attenuate nutritional decline, muscle…
